News

Nonprofit organizations CureDuchenne and Art In Giving are co-hosting a “Dealing for Duchenne” charity event in Cambridge, Massachusetts, on Oct. 20 to support the quest for a Duchenne muscular dystrophy (DMD) cure. Cambridge will emulate vintage Vegas for a one-off night featuring poker, blackjack, and other classic…

Translarna (ataluren) is a promising drug for the treatment of Duchenne muscular dystrophy (DMD) and cystic fibrosis. A team of scientists at University of Massachusetts Medical School and the University of Alabama at Birmingham has provided additional knowledge into Translarna’s mechanism of action, advancing our understanding of how the drug works to…

Using a newly engineered tongue-on-a-chip model of Duchenne muscular dystrophy, researchers found one reason that muscle regeneration fails — muscle stem cells react poorly to signals telling them new muscles need to be formed. The study,  “A human in vitro model of Duchenne muscular dystrophy muscle formation and contractility,” published in the…

Elixirgen has announced the launch of its new Quick-Tissue 1.0 Series for use by scientists exploring new ways of treating muscle-degenerative diseases like muscular dystrophy (MD). The biopharmaceutical company, located at Johns Hopkins campus, specializes in stem cell biology. The Quick-Tissue 1.0 Series includes a skeletal muscle differentiation kit called…

Researchers from Saudi Arabia demonstrated that a neurological panel assay that they developed, offers a high diagnostic yield for limb girdle muscular dystrophy (LGMD) and other myopathies.

Idera Pharmaceuticals recently presented preclinical data regarding the gene-silencing mechanisms of its third generation antisense (3GA) technology platform, a potential therapeutic for diseases that include, but are not limited to, facioscapulohumeral muscular dystrophy (FSHD). The presentations took place at the recent 12th Annual Meeting of the Oligonucleotide Therapeutics Society in Montreal,…

Summit Therapeutics announced that it has received a Rare Pediatric Disease designation from the U.S. Food and Drug Administration (FDA) for its lead drug candidate, ezutromid, as a treatment for Duchenne muscular dystrophy (DMD). The FDA defines Rare Pediatric Diseases as disorders that primarily affect people from birth to age…

Capricor Therapeutics, Inc. announced that the U.S. Department of Defense (DoD) has awarded the company a $2.4 million grant to establish a scalable, commercially-ready process to manufacture CAP-2003, the company’s proprietary exosome product candidate. Capricor is a clinical-stage biotechnology company working on the discovery, development and commercialization of biological therapies.

Researchers at Columbia University Medical Center (CUMC) have succeeded in using high-resolution electron microscopy visualize the intracellular channel involved in the contraction of the skeletal muscle. The study, “Structural Basis for Gating and Activation of RyR1,” was published in Cell. A number of conditions are known to affect various body…

Children with Duchenne muscular dystrophy (DMD) show signs of excessive activity in certain leg muscles, an apparent reaction by the body to compensate for the instability caused by muscle weakness associated with this disease. This compensation mechanism may have a negative impact on the muscles and increase the effort necessary…